PTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluation

RTTNews | 358天前
PTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluation

(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced Monday that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP for re-evaluation.

As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC has asked the CHMP to further consider the totality of evidence, including data from patient registries and real-world evidence, in a revised opinion.

In addition, the European Medicines Agency (EMA) has informed PTC that the decision has been taken to consider the Scientific Advisory Group (SAG) meeting for Translarna held on September 5, 2023, and all the procedural steps that followed, as invalid.

Furthermore, the input from the SAG meeting held in September 2023 as well as the meeting held in January 2024 will not be considered by the CHMP in any future evaluation of Translarna.

Given the inability to accurately forecast the upside impact of the continued authorization of Translarna in Europe on 2024 revenue, PTC will pause 2024 total revenue guidance at this time.

read more
FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency

FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency

The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of aromatic L-amino acid decarboxylase or AADC deficiency. Kebilidi is the first FDA-approved gene therapy for the deficiency. PTC shares gained around 8.5 percent in the extended trading on the Nasdaq on Thursday.
RTTNews | 180天前
PTC Therapeutics Granted Marketing Authorization By EU For Upstaza To Treat AADC Deficiency

PTC Therapeutics Granted Marketing Authorization By EU For Upstaza To Treat AADC Deficiency

PTC Therapeutics, Inc. (PTCT) announced Wednesday that Upstaza (eladocagene exuparvovec) was granted marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older.
RTTNews | 1028天前
Sensex, Nifty Open Higher On Rate Cut Hopes

Sensex, Nifty Open Higher On Rate Cut Hopes

Indian shares were notably higher on Wednesday as signs of easing retail inflation sparked hopes for more rate cuts from the Reserve Bank of India in coming months.
RTTNews | 2分钟前
Australian Market Maintains Slight Losses In Mid-market

Australian Market Maintains Slight Losses In Mid-market

The Australian stock market is maintaining its slight losses in mid-market moves on Wednesday, snapping a five-session winning streak, with the benchmark S&P/ASX 200 staying well below the 8,300 level, following the mixed cues from Wall Street overnight, with a mixed performance across most sectors. Traders are also booking some profits following the recent upside in the markets.
RTTNews | 55分钟前
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian stock markets are trading mixed on Wednesday, following the mixed cues from Wall Street overnight, as traders assess the impact a temporary US-China tariff war settlement, under which tariffs will be reduced to 30 percent and 10 percent, respectively, for a 90-day period. They also cautiously await trade deals with other major US trading partners. Asian markets closed mixed on Tuesday.
RTTNews | 1小时40分钟前
Sensex, Nifty Seen Higher At Open

Sensex, Nifty Seen Higher At Open

Indian shares look set to open on a positive note Wednesday after official data showed India's consumer price inflation eased further in April to the lowest level in nearly six years amid a slower rise in food prices.
RTTNews | 1小时59分钟前
Thai Bourse Likely To Remain Rangebound

Thai Bourse Likely To Remain Rangebound

The Thai stock market has alternated between positive and negative finishes through the previous five trading days since the end of the five-day winning streak in which it had advanced more than 50 points or 4.3 percent. The Stock Exchange of Thailand now sits just beneath the 1,215-point plateau and it's poised to inch higher again on Wednesday.
RTTNews | 2小时31分钟前
Japanese Market Notably Lower

Japanese Market Notably Lower

The Japanese stock market is trading notably lower on Wednesday after opening in the green, snapping a four-session winning streak, following the mixed cues from Wall Street overnight. The Nikkei 225 is falling to near the 37,900 level, with weakness in exporters and automaker stocks partially offset by gains in technology and financial stocks.
RTTNews | 2小时59分钟前